{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:41Z","timestamp":1792839701245,"version":"4.5.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12072-022-10390-z","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T06:02:44Z","timestamp":1658728964000},"page":"1001-1019","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5"],"prefix":"10.1007","volume":"16","author":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"10390_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"GM Lauer","year":"2001","unstructured":"Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41\u201352","journal-title":"N Engl J Med"},{"key":"10390_CR2","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJMra2033539","volume":"384","author":"P Cacoub","year":"2021","unstructured":"Cacoub P, Saadoun D. Extrahepatic manifestations of chronic HCV infection. N Engl J Med 2021;384:1038\u20131052","journal-title":"N Engl J Med"},{"key":"10390_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","unstructured":"Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161\u2013176","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10390_CR4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.kint.2018.11.038","volume":"95","author":"M Jadoul","year":"2019","unstructured":"Jadoul M, Bieber BA, Martin P, Akiba T, Nwankwo C, Arduino JM, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int. 2019;95:939\u2013947","journal-title":"Kidney Int"},{"key":"10390_CR5","unstructured":"World Health Organization (2022) Global hepatitis report, 2017. https:\/\/www.who.int\/publications\/i\/item\/global-hepatitis-report-2017. Accessed 05 June 2022"},{"key":"10390_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1440-1746.2010.06488.x","volume":"26","author":"CH Liu","year":"2011","unstructured":"Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol 2011;26:228\u2013239","journal-title":"J Gastroenterol Hepatol"},{"key":"10390_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41581-018-0081-8","volume":"15","author":"S Pol","year":"2019","unstructured":"Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol 2019;15:73\u201386","journal-title":"Nat Rev Nephrol"},{"key":"10390_CR8","doi-asserted-by":"publisher","first-page":"7544","DOI":"10.3748\/wjg.v20.i24.7544","volume":"20","author":"A Ozkok","year":"2014","unstructured":"Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol 2014;20:7544\u20137554","journal-title":"World J Gastroenterol"},{"key":"10390_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/hep.29505","volume":"67","author":"H Park","year":"2018","unstructured":"Park H, Chen C, Wang W, Henry L, Cook RL, Nelson DR. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology 2018;67:492\u2013504","journal-title":"Hepatology"},{"key":"10390_CR10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4254\/wjh.v9.i19.833","volume":"9","author":"M Ladino","year":"2017","unstructured":"Ladino M, Pedraza F, Roth D. Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. World J Hepatol 2017;9:833\u2013839","journal-title":"World J Hepatol"},{"key":"10390_CR11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/039139880002301205","volume":"23","author":"F Fabrizi","year":"2000","unstructured":"Fabrizi F, Martin P, Lunghi G, Ponticelli C. Nosocomial transmission of hepatitis C virus infection in hemodialysis patients: clinical perspectives. Int J Artif Organs 2000;23:805\u2013816","journal-title":"Int J Artif Organs"},{"key":"10390_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/jhep.2002.34613","volume":"36","author":"F Fabrizi","year":"2002","unstructured":"Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002;36:3\u201310","journal-title":"Hepatology"},{"key":"10390_CR13","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1093\/ndt\/gfn684","volume":"24","author":"DW Johnson","year":"2009","unstructured":"Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transpl 2009;24:1598\u20131603","journal-title":"Nephrol Dial Transplant"},{"key":"10390_CR14","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.ekir.2020.05.001","volume":"5","author":"PK Li","year":"2020","unstructured":"Li PK, Bavanandan S, Mohamed R, Szeto CC, Wong VW, Chow KM, et al. 2018 Kidney Disease: Improving Global Outcomes (KDIGO) hepatitis C in chronic kidney disease guideline implementation: Asia summit conference report. Kidney Int Rep 2020;5:1129\u20131138","journal-title":"Kidney Int Rep"},{"key":"10390_CR15","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2215\/CJN.00470107","volume":"2","author":"LS Dalrymple","year":"2007","unstructured":"Dalrymple LS, Koepsell T, Sampson J, Louie T, Dominitz JA, Young B, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol 2007;2:715\u2013721","journal-title":"Clin J Am Soc Nephrol"},{"key":"10390_CR16","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/jvh.12199","volume":"21","author":"WC Li","year":"2014","unstructured":"Li WC, Lee YY, Chen IC, Wang SH, Hsiao CT, Loke SS. Age and gender differences in the relationship between hepatitis C infection and all stages of chronic kidney disease. J Viral Hepat 2014;21:706\u2013715","journal-title":"J Viral Hepat"},{"key":"10390_CR17","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/ki.2013.455","volume":"85","author":"YC Chen","year":"2014","unstructured":"Chen YC, Lin HY, Li CY, Lee MS, Su YC. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int 2014;85:1200\u20131207","journal-title":"Kidney Int"},{"key":"10390_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100790","volume":"9","author":"JJ Lee","year":"2014","unstructured":"Lee JJ, Lin MY, Chang JS, Hung CC, Chang JM, Chen HC, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One 2014;9: e100790","journal-title":"PLoS One"},{"key":"10390_CR19","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2215\/CJN.01530218","volume":"13","author":"SY Tartof","year":"2018","unstructured":"Tartof SY, Hsu JW, Wei R, Rubenstein KB, Hu H, Arduino JM, et al. Kidney function decline in patients with CKD and untreated hepatitis C infection. Clin J Am Soc Nephrol 2018;13:1471\u20131478","journal-title":"Clin J Am Soc Nephrol"},{"key":"10390_CR20","doi-asserted-by":"publisher","first-page":"17197","DOI":"10.1038\/s41598-021-96782-x","volume":"11","author":"CK Hsu","year":"2021","unstructured":"Hsu CK, Lai TS, Chen YT, Tseng YJ, Lee CC, Chen CY, et al. Renal function trajectories in hepatitis C infection: differences between renal healthy and chronic kidney disease individuals. Sci Rep 2021;11:17197","journal-title":"Sci Rep"},{"key":"10390_CR21","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1111\/j.1572-0241.2001.03701.x","volume":"96","author":"N Furusyo","year":"2001","unstructured":"Furusyo N, Hayashi J, Kakuda K, Ariyama I, Kanamoto-Tanaka Y, Shimizu C, et al. Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study. Am J Gastroenterol 2001;96:1592\u20131600","journal-title":"Am J Gastroenterol"},{"key":"10390_CR22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1086\/655682","volume":"51","author":"CH Liu","year":"2010","unstructured":"Liu CH, Liang CC, Liu CJ, Lin JW, Chen SI, Hung PH, et al. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis 2010;51:541\u2013549","journal-title":"Clin Infect Dis"},{"key":"10390_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/MCG.0b013e31802dc57f","volume":"42","author":"LB Lemos","year":"2008","unstructured":"Lemos LB, Perez RM, Matos CA, Silva IS, Silva AE, Ferraz ML. Clinical and laboratory characteristics of acute hepatitis C in patients with end-stage renal disease on hemodialysis. J Clin Gastroenterol 2008;42:208\u2013211","journal-title":"J Clin Gastroenterol"},{"key":"10390_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00004836-200003000-00012","volume":"30","author":"N Yuki","year":"2000","unstructured":"Yuki N, Ishida H, Inoue T, Tabata T, Matsushita Y, Kishimoto H, et al. Reappraisal of biochemical hepatitis C activity in hemodialysis patients. J Clin Gastroenterol 2000;30:187\u2013194","journal-title":"J Clin Gastroenterol"},{"key":"10390_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jcv.2005.09.010","volume":"35","author":"EP Lopes","year":"2006","unstructured":"Lopes EP, Gouveia EC, Albuquerque AC, Sette LH, Mello LA, Moreira RC, et al. Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia. J Clin Virol 2006;35:298\u2013302","journal-title":"J Clin Virol"},{"key":"10390_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/003655902762467611","volume":"36","author":"I Milotic","year":"2002","unstructured":"Milotic I, Pavic I, Maleta I, Troselj-Vukic B, Milotic F. Modified range of alanine aminotransferase is insufficient for screening of hepatitis C virus infection in hemodialysis patients. Scand J Urol Nephrol 2002;36:447\u2013449","journal-title":"Scand J Urol Nephrol"},{"key":"10390_CR27","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2215\/CJN.01330308","volume":"3","author":"JE Trevizoli","year":"2008","unstructured":"Trevizoli JE, de Paula MR, Ribeiro Velasco LF, Amorim R, de Carvalho MB, et al. Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients. Clin J Am Soc Nephrol 2008;3:1385\u20131390","journal-title":"Clin J Am Soc Nephrol"},{"key":"10390_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000100892","volume":"27","author":"LB Lemos","year":"2007","unstructured":"Lemos LB, Perez RM, Lemos MM, Lanzoni VP, Draibe SA, Silva IS, et al. Hepatitis C in chronic kidney disease: predialysis patients present more severe histological liver injury than hemodialysis patients? Am J Nephrol 2007;27:191\u2013196","journal-title":"Am J Nephrol"},{"key":"10390_CR29","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/hep.29192","volume":"66","author":"TS Lai","year":"2017","unstructured":"Lai TS, Lee MH, Yang HI, You SL, Lu SN, Wang LY, et al. Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study. Hepatology 2017;66:784\u2013793","journal-title":"Hepatology"},{"key":"10390_CR30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.kint.2017.03.021","volume":"92","author":"TS Lai","year":"2017","unstructured":"Lai TS, Lee MH, Yang HI, You SL, Lu SN, Wang LY, et al. High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease. Kidney Int 2017;92:703\u2013709","journal-title":"Kidney Int"},{"key":"10390_CR31","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/ndt\/gfm028","volume":"22","author":"FK de Paula","year":"2007","unstructured":"de Paula FK, Carmo RA, de Figueiredo Antunes CM, Serufo JC, Nobre J\u00fanior VA, Fonseca de Castro LP, et al. Hepatitis C, HCV genotypes and hepatic siderosis in patients with chronic renal failure on haemodialysis in Brazil. Nephrol Dial Transpl 2007;22:2027\u20132031","journal-title":"Nephrol Dial Transpl"},{"key":"10390_CR32","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2893.2007.00868.x","volume":"14","author":"F Fabrizi","year":"2007","unstructured":"Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007;14:697\u2013703","journal-title":"J Viral Hepat"},{"key":"10390_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","volume":"19","author":"F Fabrizi","year":"2012","unstructured":"Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 2012;19:601\u2013607","journal-title":"J Viral Hepat"},{"key":"10390_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2215\/CJN.07940716","volume":"12","author":"DA Goodkin","year":"2017","unstructured":"Goodkin DA, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni RL. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol 2017;12:287\u2013297","journal-title":"Clin J Am Soc Nephrol"},{"key":"10390_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2893.2009.01151.x","volume":"17","author":"WA Henderson","year":"2010","unstructured":"Henderson WA, Shankar R, Gill JM, Kim KH, Ghany MG, Skanderson M, et al. Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. J Viral Hepat 2010;17:59\u201364","journal-title":"J Viral Hepat"},{"key":"10390_CR36","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.jfma.2021.12.019","volume":"121","author":"JJ Lee","year":"2022","unstructured":"Lee JJ, Chang JM, Yang LJ, Hsu CC, Lin MH, Lin MY. Trends of treated hepatitis B, hepatitis C, and tuberculosis infection in long-term hemodialysis patients in Taiwan: a nationwide survey in 2010\u20132018. J Formos Med Assoc 2022;121:S73-81","journal-title":"J Formos Med Assoc"},{"key":"10390_CR37","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/TP.0b013e3182848de2","volume":"95","author":"A Ingsathit","year":"2013","unstructured":"Ingsathit A, Kamanamool N, Thakkinstian A, Sumethkul V. Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: a systematic review and meta-analysis. Transplantation 2013;95:943\u2013948","journal-title":"Transplantation"},{"key":"10390_CR38","first-page":"247","volume":"11","author":"Z Rostami","year":"2011","unstructured":"Rostami Z, Nourbala MH, Alavian SM, Bieraghdar F, Jahani Y, Einollahi B. The impact of Hepatitis C virus infection on kidney transplantation outcomes: a systematic review of 18 observational studies: the impact of HCV on renal transplantation. Hepat Mon 2011;11:247\u2013254","journal-title":"Hepat Mon"},{"key":"10390_CR39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/jvh.12148","volume":"21","author":"F Fabrizi","year":"2014","unstructured":"Fabrizi F, Martin P, Dixit V, Messa P. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat 2014;21:314\u2013324","journal-title":"J Viral Hepat"},{"key":"10390_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000355615","volume":"38","author":"DA Goodkin","year":"2013","unstructured":"Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol 2013;38:405\u2013412","journal-title":"Am J Nephrol"},{"key":"10390_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002113","volume":"94","author":"YH Hsu","year":"2015","unstructured":"Hsu YH, Hung PH, Muo CH, Tsai WC, Hsu CC, Kao CH. Interferon-based treatment of hepatitis C virus infection reduces all-cause mortality in patients with end-stage renal disease: an 8-year nationwide cohort study in Taiwan. Medicine (Baltimore) 2015;94: e2113","journal-title":"Medicine (Baltimore)"},{"key":"10390_CR42","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jhep.2017.12.003","volume":"68","author":"J S\u00f6derholm","year":"2018","unstructured":"S\u00f6derholm J, Millbourn C, B\u00fcsch K, K\u00f6vamees J, Schvarcz R, Lindahl K, et al. Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis. J Hepatol 2018;68:904\u2013911","journal-title":"J Hepatol"},{"key":"10390_CR43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4318\/tjg.2009.0020","volume":"20","author":"F Aky\u00fcz","year":"2009","unstructured":"Aky\u00fcz F, Be\u015fi\u015fik F, Pinarba\u015fi B, Demir K, Kaymako\u011flu ST, Cakalo\u011flu Y, et al. The quality of life in hemodialysis patients with chronic hepatitis C virus infection. Turk J Gastroenterol 2009;20:243\u2013246","journal-title":"Turk J Gastroenterol"},{"key":"10390_CR44","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/gut.2007.133884","volume":"57","author":"CH Liu","year":"2008","unstructured":"Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008;57:525\u2013530","journal-title":"Gut"},{"key":"10390_CR45","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jhep.2018.12.036","volume":"70","author":"H Fontaine","year":"2019","unstructured":"Fontaine H, Alric L, Labreuche J, Legendre B, Louvet A, Antoine C, et al. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. J Hepatol 2019;70:831\u2013838","journal-title":"J Hepatol"},{"key":"10390_CR46","doi-asserted-by":"publisher","first-page":"729","DOI":"10.7326\/0003-4819-159-11-201312030-00005","volume":"159","author":"CH Liu","year":"2013","unstructured":"Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, et al. Pegylated interferon-\u03b12a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013;159:729\u2013738","journal-title":"Ann Intern Med"},{"key":"10390_CR47","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1136\/gutjnl-2014-307080","volume":"64","author":"CH Liu","year":"2015","unstructured":"Liu CH, Liu CJ, Huang CF, Lin JW, Dai CY, Liang CC, et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut 2015;64:303\u2013311","journal-title":"Gut"},{"key":"10390_CR48","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1053\/j.ajkd.2013.03.037","volume":"62","author":"PL Tseng","year":"2013","unstructured":"Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, et al. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts. Am J Kidney Dis 2013;62:789\u2013795","journal-title":"Am J Kidney Dis"},{"key":"10390_CR49","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol 2020;73:1170\u20131218","journal-title":"J Hepatol"},{"key":"10390_CR50","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/cid\/ciy585","volume":"67","author":"AASLD-IDSA HCV Guidance Panel","year":"2018","unstructured":"AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67:1477\u20131492","journal-title":"Clin Infect Dis"},{"key":"10390_CR51","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","volume":"10","author":"M Omata","year":"2016","unstructured":"Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016;10:702\u2013726","journal-title":"Hepatol Int"},{"key":"10390_CR52","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12072-018-9915-5","volume":"13","author":"T Kanda","year":"2019","unstructured":"Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, et al. APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Hepatol Int 2019;13:103\u2013109","journal-title":"Hepatol Int"},{"key":"10390_CR53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40264-016-0420-2","volume":"39","author":"EJ Smolders","year":"2016","unstructured":"Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and\/or renal impairment. Drug Saf 2016;39:589\u2013611","journal-title":"Drug Saf"},{"key":"10390_CR54","doi-asserted-by":"publisher","first-page":"e01990","DOI":"10.1128\/AAC.01990-17","volume":"62","author":"MP Kosloski","year":"2018","unstructured":"Kosloski MP, Zhao W, Marbury TC, Preston RA, Collins MG, Pugatch D, et al. Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of the glecaprevir and pibrentasvir combination in hepatitis C virus-negative subjects. Antimicrob Agents Chemother 2018;62:e01990-e2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10390_CR55","doi-asserted-by":"publisher","first-page":"S590","DOI":"10.1016\/S0168-8278(15)30915-6","volume":"62","author":"E Mogalian","year":"2015","unstructured":"Mogalian E, Mathias A, Brainard D, Shen G, McNally J, Sajwani K, et al. The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment. J Hepatol 2015;62:S590\u2013S591","journal-title":"J Hepatol"},{"key":"10390_CR56","doi-asserted-by":"publisher","first-page":"S613","DOI":"10.1016\/S0168-8278(16)01135-1","volume":"64","author":"E Lawitz","year":"2016","unstructured":"Lawitz E, Marbury T, Kirby BJ, Au NT, Mathias A, Stamm LM, et al. The effect of renal or hepatic impairment on the pharmacokinetics of GS-9857, a pangenotypic HCV NS3\/4A protease inhibitor. J Hepatol 2016;64:S613","journal-title":"J Hepatol"},{"key":"10390_CR57","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40265-014-0247-z","volume":"74","author":"GM Keating","year":"2014","unstructured":"Keating GM. Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs 2014;74:1127\u20131146","journal-title":"Drugs"},{"key":"10390_CR58","doi-asserted-by":"publisher","first-page":"S433","DOI":"10.1016\/S0168-8278(12)61113-1","volume":"56","author":"MT Cornpropst","year":"2012","unstructured":"Cornpropst MT, Denning JM, Clemons D, Marbury TC, Alcorn H, Smith WB, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. J Hepatol 2012;56:S433","journal-title":"J Hepatol"},{"key":"10390_CR59","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","volume":"65","author":"A Desnoyer","year":"2016","unstructured":"Desnoyer A, Pospai D, L\u00ea MP, Gervais A, Heurgu\u00e9-Berlot A, Laradi A, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 2016;65:40\u201347","journal-title":"J Hepatol"},{"key":"10390_CR60","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3350\/cmh.2020.0180","volume":"27","author":"PY Hsu","year":"2021","unstructured":"Hsu PY, Wei YJ, Lee JJ, Niu SW, Huang JC, Hsu CT, et al. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. Clin Mol Hepatol 2021;27:186\u2013196","journal-title":"Clin Mol Hepatol"},{"key":"10390_CR61","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.15011","volume":"48","author":"CH Liu","year":"2018","unstructured":"Liu CH, Yu ML, Peng CY, Hsieh TY, Huang YH, Su WW, et al. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. Aliment Pharmacol Ther 2018;48:1290\u20131300","journal-title":"Aliment Pharmacol Ther"},{"key":"10390_CR62","unstructured":"University of Liverpool HEP Drug Interactions Checker (2022). https:\/\/www.hep-druginteractions.org\/checker. Accessed 05 June 2022"},{"key":"10390_CR63","unstructured":"University of Liverpool COVID-19 Drug Interactions Checker (2022). https:\/\/www.covid19-druginteractions.org\/checker. Accessed 05 June 2022"},{"key":"10390_CR64","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","volume":"377","author":"E Gane","year":"2017","unstructured":"Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Br\u00e4u N, Brown A, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 2017;377:1448\u20131455","journal-title":"N Engl J Med"},{"key":"10390_CR65","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/liv.14320","volume":"40","author":"E Lawitz","year":"2020","unstructured":"Lawitz E, Flisiak R, Abunimeh M, Sise ME, Park JY, Kaskas M, et al. Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int 2020;40:1032\u20131041","journal-title":"Liver Int"},{"key":"10390_CR66","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jvh.13265","volume":"27","author":"CH Liu","year":"2020","unstructured":"Liu CH, Yang SS, Peng CY, Lin WT, Liu CJ, Su TH, et al. Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. J Viral Hepat 2020;27:568\u2013575","journal-title":"J Viral Hepat"},{"key":"10390_CR67","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/apt.15218","volume":"49","author":"M Atsukawa","year":"2019","unstructured":"Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, et al. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther 2019;49:1230\u20131241","journal-title":"Aliment Pharmacol Ther"},{"key":"10390_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237582","volume":"15","author":"HH Yen","year":"2020","unstructured":"Yen HH, Su PY, Zeng YH, Liu IL, Huang SP, Hsu YC, et al. Glecaprevir-pibrentasvir for chronic hepatitis C: comparing treatment effect in patients with and without end-stage renal disease in a real-world setting. PLoS One 2020;15: e0237582","journal-title":"PLoS ONE"},{"key":"10390_CR69","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00535-019-01556-y","volume":"54","author":"G Suda","year":"2019","unstructured":"Suda G, Hasebe C, Abe M, Kurosaki M, Itakura J, Izumi N, et al. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. J Gastroenterol 2019;54:641\u2013649","journal-title":"J Gastroenterol"},{"key":"10390_CR70","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3350\/cmh.2020.0058","volume":"26","author":"DYH Yap","year":"2020","unstructured":"Yap DYH, Liu KSH, Hsu YC, Wong GLH, Tsai MC, Chen CH, et al. Use of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. Clin Mol Hepatol 2020;26:554\u2013561","journal-title":"Clin Mol Hepatol"},{"key":"10390_CR71","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/MEG.0000000000001923","volume":"34","author":"K Stein","year":"2022","unstructured":"Stein K, Stoehr A, Klinker H, Teuber G, Naumann U, John C, et al. Hepatitis C therapy with grazoprevir\/elbasvir and glecaprevir\/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). Eur J Gastroenterol Hepatol 2022;34:76\u201383","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10390_CR72","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","volume":"71","author":"SM Borgia","year":"2019","unstructured":"Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, et al. Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol 2019;71:660\u2013665","journal-title":"J Hepatol"},{"key":"10390_CR73","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/gutjnl-2020-323569","volume":"71","author":"CH Liu","year":"2022","unstructured":"Liu CH, Chen CY, Su WW, Tseng KC, Lo CC, Liu CJ, et al. Sofosbuvir\/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. Gut 2022;71:176\u2013184","journal-title":"Gut"},{"key":"10390_CR74","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1136\/gutjnl-2020-323277","volume":"70","author":"ML Yu","year":"2021","unstructured":"Yu ML, Huang CF, Wei YJ, Lin WY, Lin YH, Hsu PY, et al. Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). Gut 2021;70:2349\u20132358","journal-title":"Gut"},{"key":"10390_CR75","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jceh.2019.10.004","volume":"10","author":"N Gaur","year":"2020","unstructured":"Gaur N, Malhotra V, Agrawal D, Singh SK, Beniwal P, Sharma S, et al. Sofosbuvir-velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation. J Clin Exp Hepatol 2020;10:189\u2013193","journal-title":"J Clin Exp Hepatol"},{"key":"10390_CR76","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/liv.14685","volume":"41","author":"S Taneja","year":"2021","unstructured":"Taneja S, Duseja A, Mehta M, De A, Verma N, Premkumar M, et al. Sofosbuvir and velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis. Liver Int 2021;41:705\u2013709","journal-title":"Liver Int"},{"key":"10390_CR77","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jhep.2019.11.014","volume":"72","author":"CH Liu","year":"2020","unstructured":"Liu CH, Lee MH, Lin JW, Liu CJ, Su TH, Tseng TC, et al. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. J Hepatol 2020;72:839\u2013846","journal-title":"J Hepatol"},{"key":"10390_CR78","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nep.13968","volume":"27","author":"A De","year":"2022","unstructured":"De A, Roy A, Verma N, Mishra S, Premkumar M, Taneja S, et al. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: a systematic review and meta-analysis. Nephrology (Carlton) 2022;27:82\u201389","journal-title":"Nephrology (Carlton)"},{"key":"10390_CR79","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/hep.30046","volume":"68","author":"N Reau","year":"2018","unstructured":"Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, et al. Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology 2018;68:1298\u20131307","journal-title":"Hepatology"},{"key":"10390_CR80","doi-asserted-by":"publisher","first-page":"SP786","DOI":"10.1093\/ndt\/gfz103.SP786","volume":"34","author":"R Greco","year":"2019","unstructured":"Greco R, Papalia T, Bonofiglio R. Efficacy and safety of sofosbuvir and velpatasvir in renal transplant recipients with chronic hepatitis C virus infection. Nephrol Dial Transpl 2019;34:SP786","journal-title":"Nephrol Dial Transpl"},{"key":"10390_CR81","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1056\/NEJMp1505074","volume":"373","author":"PP Reese","year":"2015","unstructured":"Reese PP, Abt PL, Blumberg EA, Goldberg DS. Transplanting hepatitis C-positive kidneys. N Engl J Med 2015;373:303\u2013305","journal-title":"N Engl J Med"},{"key":"10390_CR82","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMc1705221","volume":"376","author":"DS Goldberg","year":"2017","unstructured":"Goldberg DS, Abt PL, Blumberg EA, Van Deerlin VM, Levine M, Reddy KR, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med 2017;376:2394\u20132395","journal-title":"N Engl J Med"},{"key":"10390_CR83","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/M17-2871","volume":"168","author":"CM Durand","year":"2018","unstructured":"Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, et al. Direct-acting antiviral prophylaxis in kidney transplantation from Hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med 2018;168:533\u2013540","journal-title":"Ann Intern Med"},{"key":"10390_CR84","doi-asserted-by":"publisher","first-page":"273","DOI":"10.7326\/M18-0749","volume":"169","author":"PP Reese","year":"2018","unstructured":"Reese PP, Abt PL, Blumberg EA, Van Deerlin VM, Bloom RD, Potluri VS, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med 2018;169:273\u2013281","journal-title":"Ann Intern Med"},{"key":"10390_CR85","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1681\/ASN.2020050686","volume":"31","author":"ME Sise","year":"2020","unstructured":"Sise ME, Goldberg DS, Kort JJ, Schaubel DE, Alloway RR, Durand CM, et al. Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. J Am Soc Nephrol 2020;31:2678\u20132687","journal-title":"J Am Soc Nephrol"},{"key":"10390_CR86","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M20-1468","volume":"174","author":"CM Durand","year":"2021","unstructured":"Durand CM, Barnaba B, Yu S, Brown DM, Chattergoon MA, Bair N, et al. Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label nonrandomized study. Ann Intern Med 2021;174:137\u2013138","journal-title":"Ann Intern Med"},{"key":"10390_CR87","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","volume":"5","author":"JJ Feld","year":"2020","unstructured":"Feld JJ, Cypel M, Kumar D, Dahari H, Pinto Ribeiro RV, Marks N, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol 2020;5:649\u2013657","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10390_CR88","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1053\/j.ajkd.2020.10.017","volume":"77","author":"MZ Molnar","year":"2021","unstructured":"Molnar MZ, Azhar A, Tsujita M, Talwar M, Balaraman V, Bhalla A, et al. Transplantation of kidneys from hepatitis C virus-infected donors to hepatitis C virus-negative recipients: one-year kidney allograft outcomes. Am J Kidney Dis 2021;77:739\u201347.e1","journal-title":"Am J Kidney Dis"},{"key":"10390_CR89","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.31011","volume":"72","author":"N Kapila","year":"2020","unstructured":"Kapila N, Menon KVN, Al-Khalloufi K, Vanatta JM, Murgas C, Reino D, et al. Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: a real-world experience. Hepatology 2020;72:32\u201341","journal-title":"Hepatology"},{"key":"10390_CR90","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13833","volume":"34","author":"JA Graham","year":"2020","unstructured":"Graham JA, Torabi J, Ajaimy M, Akalin E, Liriano LE, Azzi Y, et al. Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access. Clin Transpl 2020;34: e13833","journal-title":"Clin Transplant"},{"key":"10390_CR91","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13540","volume":"23","author":"N Jandovitz","year":"2021","unstructured":"Jandovitz N, Nair V, Grodstein E, Molmenti E, Fahmy A, Abate M, et al. Hepatitis C-positive donor to negative recipient kidney transplantation: a real-world experience. Transpl Infect Dis 2021;23: e13540","journal-title":"Transpl Infect Dis"},{"key":"10390_CR92","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13449","volume":"23","author":"J Torabi","year":"2021","unstructured":"Torabi J, Rocca JP, Ajaimy M, Melvin J, Campbell A, Akalin E, et al. Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients. Transpl Infect Dis 2021;23: e13449","journal-title":"Transpl Infect Dis"},{"key":"10390_CR93","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/hep.31551","volume":"73","author":"NA Terrault","year":"2021","unstructured":"Terrault NA, Burton J, Ghobrial M, Verna E, Bayer J, Klein C, et al. Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-viremic donors. Hepatology 2021;73:2110\u20132123","journal-title":"Hepatology"},{"key":"10390_CR94","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/ajt.15664","volume":"20","author":"G Gupta","year":"2020","unstructured":"Gupta G, Yakubu I, Bhati CS, Zhang Y, Kang L, Patterson JA, et al. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. Am J Transpl 2020;20:739\u2013751","journal-title":"Am J Transpl"},{"key":"10390_CR95","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1111\/ajt.16747","volume":"21","author":"G Gupta","year":"2021","unstructured":"Gupta G, Yakubu I, Zhang Y, Kimball P, Kang L, Mitchell K, et al. Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants. Am J Transpl 2021;21:3734\u20133742","journal-title":"Am J Transpl"},{"key":"10390_CR96","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.933313","volume":"26","author":"R Chen","year":"2021","unstructured":"Chen R, Li D, Zhang M, Yuan X. Sofosbuvir\/velpatasvir prophylaxis for 12 weeks in hepatitis C virus (HCV)-negative recipients receiving kidney transplantation from HCV-positive donors. Ann Transpl 2021;26: e933313","journal-title":"Ann Transplant"},{"key":"10390_CR97","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ekir.2021.11.022","volume":"7","author":"ME Sise","year":"2021","unstructured":"Sise ME, Goldberg DS, Schaubel DE, Fontana RJ, Kort JJ, Alloway RR, et al. One-year outcomes of the multi-center study to transplant hepatitis C-infected kidneys (MYTHIC) trial. Kidney Int Rep 2021;7:241\u2013250","journal-title":"Kidney Int Rep"},{"key":"10390_CR98","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2019.11.005","volume":"75","author":"MH Eckman","year":"2020","unstructured":"Eckman MH, Woodle ES, Thakar CV, Alloway RR, Sherman KE. Cost-effectiveness of using kidneys from HCV-viremic donors for transplantation into HCV-uninfected recipients. Am J Kidney Dis 2020;75:857\u2013867","journal-title":"Am J Kidney Dis"},{"key":"10390_CR99","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1053\/j.ajkd.2021.03.017","volume":"78","author":"TH Hu","year":"2021","unstructured":"Hu TH, Su WW, Yang CC, Yang CC, Kuo WH, Chen YY, et al. Elimination of hepatitis C virus in a dialysis population: a collaborative care model in Taiwan. Am J Kidney Dis 2021;78:511\u2013519.e1","journal-title":"Am J Kidney Dis"},{"key":"10390_CR100","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/apt.16697","volume":"55","author":"CH Liu","year":"2022","unstructured":"Liu CH, Peng CY, Kao WY, Yang SS, Shih YL, Lin CL, et al. Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. Aliment Pharmacol Ther 2022;55:434\u2013445","journal-title":"Aliment Pharmacol Ther"},{"key":"10390_CR101","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1186\/s12879-019-4217-7","volume":"19","author":"J Zhang","year":"2019","unstructured":"Zhang J, Sun W, Lin J, Tian Y, Ma L, Zhang L, et al. Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China. BMC Infect Dis 2019;19:645","journal-title":"BMC Infect Dis"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10390-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-022-10390-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10390-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T15:04:06Z","timestamp":1744124646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-022-10390-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10390"],"URL":"https:\/\/doi.org\/10.1007\/s12072-022-10390-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"6 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chen-Hua Liu has served as a speaker for Abbott, has served as a speaker, a consultant and an advisory board member for Abbvie, Gilead Sciences, and Merck Sharp & Dohme, and has received research funding from Abbvie, Gilead Sciences, and Merck Sharp & Dohme. Jia-Horng Kao has served as a speaker, a consultant and an advisory board member for Abbott, Abbvie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial"}},{"value":"This was not an animal research.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal research"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors consented the publish the work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trials registration"}}]}}